Vision

 Providing life-savings radiation and nuclear medical countermeasures

 

Therapeutic Focus

Trocar Radiation's proprietary, tissue-targeting platform technology minimizes and reverses acute radiation syndrome. 

Our immediate priority is the fast tracking of the development of our lead radiation mitigator for the treatment of civilians, military personnel and first responders post exposure to lethal doses of radiation.

In addition, Trocar's radiation therapeutics have application as radiation protectors for the use in medical oncology procedures and as a nuclear radioprotection countermeasures.

 

Acute Radiation Syndrome

Acute Radiation Syndrome (ARS) is an acute illness caused by irradiation of the majority or entire body by a high dose of penetrating radiation in a very short period of time (usually a matter of minutes). The major cause of ARS is depletion of immature parenchymal stem cells in specific tissues (e.g. GI tract, lungs, bone marrow). 

The first cause of death in survivors of ionizing radiation exposure is gastrointestinal (GI) ARS. 

953px-Radiation_Sickness.png
Dire Need for Radiation Mitigators

Increasing global risks of nuclear/radiological accidents and terrorism continue to challenge national and global security​. There is an urgent requirement for radiation countermeasures for clinically significant ionizing radiation exposure in the case of:

  • Nuclear accidents (e.g. Fukoshima);

  • Deep space travel (e.g. Space Force, SpaceX);

  • Medical procedures; and

  • Terrorism.

There are currently no FDA drugs that treat ARS.

Therapeutic Solution
NIH_NIAID_Master_Mobile_ProductID_Logo_2
Armed_Forces_Radiobiology_Research_Insti
University%20of%20Oklahoma_edited.png

Trocar's compounds increase survival post exposure to lethal doses of radiation even at extremely high levels of radiation exposure. One of Trocar Pharma's patented lead compounds, YK-4-250, specifically treats GI ARS which untreated has a high mortality rate with death occurring 9 to 14 days post exposure.

Our in vivo and human organoid preclinical studies have successfully demonstrated Trocar's compounds ability to mitigate death due to lethal doses of radiation by reversing cell damage, increasing GI stem cell proliferation, reducing inflammation, and increasing intestinal crypt survival.​

Trocar Oncology is partnering with NIAID, the Department of Defense/Armed Forces Radiobiology Research Institute (AFRRI), and the University of Oklahoma on the development of its radiation mitigators.

Pipeline